nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—Serum creatinine increased—Doxorubicin—thyroid cancer	0.00482	0.00482	CcSEcCtD
Lurasidone—Renal failure—Sorafenib—thyroid cancer	0.00477	0.00477	CcSEcCtD
Lurasidone—Anxiety—Vandetanib—thyroid cancer	0.00477	0.00477	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00475	0.00475	CcSEcCtD
Lurasidone—Hypokinesia—Epirubicin—thyroid cancer	0.00475	0.00475	CcSEcCtD
Lurasidone—Dry mouth—Vandetanib—thyroid cancer	0.00468	0.00468	CcSEcCtD
Lurasidone—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00459	0.00459	CcSEcCtD
Lurasidone—Infection—Vandetanib—thyroid cancer	0.00455	0.00456	CcSEcCtD
Lurasidone—Nervous system disorder—Vandetanib—thyroid cancer	0.0045	0.0045	CcSEcCtD
Lurasidone—Skin disorder—Vandetanib—thyroid cancer	0.00445	0.00445	CcSEcCtD
Lurasidone—Hypokinesia—Doxorubicin—thyroid cancer	0.00439	0.00439	CcSEcCtD
Lurasidone—Urinary tract disorder—Sorafenib—thyroid cancer	0.0043	0.0043	CcSEcCtD
Lurasidone—Connective tissue disorder—Sorafenib—thyroid cancer	0.00428	0.00428	CcSEcCtD
Lurasidone—Urethral disorder—Sorafenib—thyroid cancer	0.00427	0.00427	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00418	0.00418	CcSEcCtD
Lurasidone—Insomnia—Vandetanib—thyroid cancer	0.00415	0.00415	CcSEcCtD
Lurasidone—Dyspnoea—Vandetanib—thyroid cancer	0.00409	0.00409	CcSEcCtD
Lurasidone—Cardiac disorder—Sorafenib—thyroid cancer	0.00404	0.00404	CcSEcCtD
Lurasidone—Dyspepsia—Vandetanib—thyroid cancer	0.00404	0.00404	CcSEcCtD
Lurasidone—Decreased appetite—Vandetanib—thyroid cancer	0.00399	0.00399	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00396	0.00396	CcSEcCtD
Lurasidone—Fatigue—Vandetanib—thyroid cancer	0.00395	0.00395	CcSEcCtD
Lurasidone—Angiopathy—Sorafenib—thyroid cancer	0.00395	0.00395	CcSEcCtD
Lurasidone—Arrhythmia—Sorafenib—thyroid cancer	0.00389	0.00389	CcSEcCtD
Lurasidone—Mental disorder—Sorafenib—thyroid cancer	0.00381	0.00381	CcSEcCtD
Lurasidone—Malnutrition—Sorafenib—thyroid cancer	0.00379	0.00379	CcSEcCtD
Lurasidone—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00375	0.00375	CcSEcCtD
Lurasidone—Breast pain—Epirubicin—thyroid cancer	0.00367	0.00367	CcSEcCtD
Lurasidone—Amenorrhoea—Epirubicin—thyroid cancer	0.00365	0.00365	CcSEcCtD
Lurasidone—Cardiovascular disorder—Epirubicin—thyroid cancer	0.00365	0.00365	CcSEcCtD
Lurasidone—Muscle spasms—Sorafenib—thyroid cancer	0.00364	0.00364	CcSEcCtD
Lurasidone—Abdominal pain—Vandetanib—thyroid cancer	0.00362	0.00362	CcSEcCtD
Lurasidone—Anaemia—Sorafenib—thyroid cancer	0.0035	0.0035	CcSEcCtD
Lurasidone—Angioedema—Sorafenib—thyroid cancer	0.00346	0.00346	CcSEcCtD
Lurasidone—Dyskinesia—Epirubicin—thyroid cancer	0.00341	0.00341	CcSEcCtD
Lurasidone—Syncope—Sorafenib—thyroid cancer	0.0034	0.0034	CcSEcCtD
Lurasidone—Breast pain—Doxorubicin—thyroid cancer	0.0034	0.0034	CcSEcCtD
Lurasidone—Leukopenia—Sorafenib—thyroid cancer	0.00339	0.00339	CcSEcCtD
Lurasidone—Dysarthria—Epirubicin—thyroid cancer	0.00339	0.00339	CcSEcCtD
Lurasidone—Amenorrhoea—Doxorubicin—thyroid cancer	0.00337	0.00337	CcSEcCtD
Lurasidone—Cardiovascular disorder—Doxorubicin—thyroid cancer	0.00337	0.00337	CcSEcCtD
Lurasidone—Creatinine increased—Epirubicin—thyroid cancer	0.00337	0.00337	CcSEcCtD
Lurasidone—Loss of consciousness—Sorafenib—thyroid cancer	0.00333	0.00333	CcSEcCtD
Lurasidone—Atrioventricular block—Epirubicin—thyroid cancer	0.0033	0.0033	CcSEcCtD
Lurasidone—Asthenia—Vandetanib—thyroid cancer	0.00329	0.00329	CcSEcCtD
Lurasidone—Gait disturbance—Epirubicin—thyroid cancer	0.00328	0.00328	CcSEcCtD
Lurasidone—Hypertension—Sorafenib—thyroid cancer	0.00327	0.00327	CcSEcCtD
Lurasidone—Pruritus—Vandetanib—thyroid cancer	0.00324	0.00324	CcSEcCtD
Lurasidone—Neck pain—Epirubicin—thyroid cancer	0.00324	0.00324	CcSEcCtD
Lurasidone—Myalgia—Sorafenib—thyroid cancer	0.00323	0.00323	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.0032	0.0032	CcSEcCtD
Lurasidone—Pulmonary embolism—Epirubicin—thyroid cancer	0.0032	0.0032	CcSEcCtD
Lurasidone—Abnormal dreams—Epirubicin—thyroid cancer	0.00317	0.00317	CcSEcCtD
Lurasidone—Dry mouth—Sorafenib—thyroid cancer	0.00316	0.00316	CcSEcCtD
Lurasidone—Dyskinesia—Doxorubicin—thyroid cancer	0.00315	0.00315	CcSEcCtD
Lurasidone—Diarrhoea—Vandetanib—thyroid cancer	0.00314	0.00314	CcSEcCtD
Lurasidone—Dysarthria—Doxorubicin—thyroid cancer	0.00313	0.00313	CcSEcCtD
Lurasidone—Creatinine increased—Doxorubicin—thyroid cancer	0.00311	0.00311	CcSEcCtD
Lurasidone—Salivary hypersecretion—Epirubicin—thyroid cancer	0.00311	0.00311	CcSEcCtD
Lurasidone—Infection—Sorafenib—thyroid cancer	0.00307	0.00307	CcSEcCtD
Lurasidone—Atrioventricular block—Doxorubicin—thyroid cancer	0.00306	0.00306	CcSEcCtD
Lurasidone—Shock—Sorafenib—thyroid cancer	0.00304	0.00304	CcSEcCtD
Lurasidone—Gait disturbance—Doxorubicin—thyroid cancer	0.00304	0.00304	CcSEcCtD
Lurasidone—Nervous system disorder—Sorafenib—thyroid cancer	0.00303	0.00303	CcSEcCtD
Lurasidone—Dizziness—Vandetanib—thyroid cancer	0.00303	0.00303	CcSEcCtD
Lurasidone—Skin disorder—Sorafenib—thyroid cancer	0.003	0.003	CcSEcCtD
Lurasidone—Neck pain—Doxorubicin—thyroid cancer	0.003	0.003	CcSEcCtD
Lurasidone—Pulmonary embolism—Doxorubicin—thyroid cancer	0.00296	0.00296	CcSEcCtD
Lurasidone—Abnormal dreams—Doxorubicin—thyroid cancer	0.00293	0.00293	CcSEcCtD
Lurasidone—Vomiting—Vandetanib—thyroid cancer	0.00292	0.00292	CcSEcCtD
Lurasidone—Rash—Vandetanib—thyroid cancer	0.00289	0.00289	CcSEcCtD
Lurasidone—Dermatitis—Vandetanib—thyroid cancer	0.00289	0.00289	CcSEcCtD
Lurasidone—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.00288	0.00288	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00282	0.00282	CcSEcCtD
Lurasidone—Dyspnoea—Sorafenib—thyroid cancer	0.00276	0.00276	CcSEcCtD
Lurasidone—Nausea—Vandetanib—thyroid cancer	0.00272	0.00272	CcSEcCtD
Lurasidone—Dyspepsia—Sorafenib—thyroid cancer	0.00272	0.00272	CcSEcCtD
Lurasidone—Decreased appetite—Sorafenib—thyroid cancer	0.00269	0.00269	CcSEcCtD
Lurasidone—Diabetes mellitus—Epirubicin—thyroid cancer	0.00267	0.00267	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00267	0.00267	CcSEcCtD
Lurasidone—Fatigue—Sorafenib—thyroid cancer	0.00267	0.00267	CcSEcCtD
Lurasidone—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00253	0.00253	CcSEcCtD
Lurasidone—Hot flush—Epirubicin—thyroid cancer	0.00249	0.00249	CcSEcCtD
Lurasidone—Increased appetite—Epirubicin—thyroid cancer	0.00248	0.00248	CcSEcCtD
Lurasidone—Diabetes mellitus—Doxorubicin—thyroid cancer	0.00247	0.00247	CcSEcCtD
Lurasidone—Menopausal symptoms—Epirubicin—thyroid cancer	0.00246	0.00246	CcSEcCtD
Lurasidone—Abdominal pain—Sorafenib—thyroid cancer	0.00244	0.00245	CcSEcCtD
Lurasidone—Lethargy—Epirubicin—thyroid cancer	0.00237	0.00237	CcSEcCtD
Lurasidone—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00237	0.00237	CcSEcCtD
Lurasidone—Osteoarthritis—Epirubicin—thyroid cancer	0.00233	0.00233	CcSEcCtD
Lurasidone—Hot flush—Doxorubicin—thyroid cancer	0.0023	0.0023	CcSEcCtD
Lurasidone—Increased appetite—Doxorubicin—thyroid cancer	0.00229	0.00229	CcSEcCtD
Lurasidone—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00228	0.00228	CcSEcCtD
Lurasidone—Asthenia—Sorafenib—thyroid cancer	0.00222	0.00222	CcSEcCtD
Lurasidone—Lethargy—Doxorubicin—thyroid cancer	0.0022	0.0022	CcSEcCtD
Lurasidone—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.0022	0.0022	CcSEcCtD
Lurasidone—Pruritus—Sorafenib—thyroid cancer	0.00219	0.00219	CcSEcCtD
Lurasidone—Blood creatinine increased—Epirubicin—thyroid cancer	0.00218	0.00218	CcSEcCtD
Lurasidone—Osteoarthritis—Doxorubicin—thyroid cancer	0.00215	0.00215	CcSEcCtD
Lurasidone—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00212	0.00212	CcSEcCtD
Lurasidone—Abdominal pain upper—Epirubicin—thyroid cancer	0.00212	0.00212	CcSEcCtD
Lurasidone—Diarrhoea—Sorafenib—thyroid cancer	0.00212	0.00212	CcSEcCtD
Lurasidone—Breast disorder—Epirubicin—thyroid cancer	0.0021	0.0021	CcSEcCtD
Lurasidone—Nasopharyngitis—Epirubicin—thyroid cancer	0.00208	0.00208	CcSEcCtD
Lurasidone—Gastritis—Epirubicin—thyroid cancer	0.00206	0.00206	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00205	0.00205	CcSEcCtD
Lurasidone—Dizziness—Sorafenib—thyroid cancer	0.00205	0.00205	CcSEcCtD
Lurasidone—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00202	0.00202	CcSEcCtD
Lurasidone—Influenza—Epirubicin—thyroid cancer	0.00201	0.00201	CcSEcCtD
Lurasidone—Dysphagia—Epirubicin—thyroid cancer	0.00201	0.00201	CcSEcCtD
Lurasidone—Eosinophilia—Epirubicin—thyroid cancer	0.00199	0.00199	CcSEcCtD
Lurasidone—Vomiting—Sorafenib—thyroid cancer	0.00197	0.00197	CcSEcCtD
Lurasidone—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00197	0.00197	CcSEcCtD
Lurasidone—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00197	0.00197	CcSEcCtD
Lurasidone—Angina pectoris—Epirubicin—thyroid cancer	0.00196	0.00196	CcSEcCtD
Lurasidone—Rash—Sorafenib—thyroid cancer	0.00195	0.00195	CcSEcCtD
Lurasidone—Dermatitis—Sorafenib—thyroid cancer	0.00195	0.00195	CcSEcCtD
Lurasidone—Breast disorder—Doxorubicin—thyroid cancer	0.00194	0.00194	CcSEcCtD
Lurasidone—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00192	0.00192	CcSEcCtD
Lurasidone—Gastritis—Doxorubicin—thyroid cancer	0.0019	0.0019	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.0019	0.0019	CcSEcCtD
Lurasidone—Neutropenia—Epirubicin—thyroid cancer	0.00188	0.00188	CcSEcCtD
Lurasidone—Dysuria—Epirubicin—thyroid cancer	0.00188	0.00188	CcSEcCtD
Lurasidone—Dysphagia—Doxorubicin—thyroid cancer	0.00186	0.00186	CcSEcCtD
Lurasidone—Influenza—Doxorubicin—thyroid cancer	0.00186	0.00186	CcSEcCtD
Lurasidone—Eosinophilia—Doxorubicin—thyroid cancer	0.00184	0.00184	CcSEcCtD
Lurasidone—Nausea—Sorafenib—thyroid cancer	0.00184	0.00184	CcSEcCtD
Lurasidone—Weight increased—Epirubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Lurasidone—Hyperglycaemia—Epirubicin—thyroid cancer	0.00181	0.00181	CcSEcCtD
Lurasidone—Angina pectoris—Doxorubicin—thyroid cancer	0.00181	0.00181	CcSEcCtD
Lurasidone—Infestation—Epirubicin—thyroid cancer	0.00179	0.00179	CcSEcCtD
Lurasidone—Infestation NOS—Epirubicin—thyroid cancer	0.00179	0.00179	CcSEcCtD
Lurasidone—Renal failure—Epirubicin—thyroid cancer	0.00176	0.00176	CcSEcCtD
Lurasidone—Urinary tract infection—Epirubicin—thyroid cancer	0.00174	0.00174	CcSEcCtD
Lurasidone—Neutropenia—Doxorubicin—thyroid cancer	0.00174	0.00174	CcSEcCtD
Lurasidone—Dysuria—Doxorubicin—thyroid cancer	0.00174	0.00174	CcSEcCtD
Lurasidone—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00169	0.0017	CcSEcCtD
Lurasidone—Weight increased—Doxorubicin—thyroid cancer	0.00169	0.00169	CcSEcCtD
Lurasidone—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00168	0.00168	CcSEcCtD
Lurasidone—Agranulocytosis—Epirubicin—thyroid cancer	0.00167	0.00167	CcSEcCtD
Lurasidone—Infestation NOS—Doxorubicin—thyroid cancer	0.00166	0.00166	CcSEcCtD
Lurasidone—Infestation—Doxorubicin—thyroid cancer	0.00166	0.00166	CcSEcCtD
Lurasidone—Bradycardia—Epirubicin—thyroid cancer	0.00164	0.00164	CcSEcCtD
Lurasidone—Renal failure—Doxorubicin—thyroid cancer	0.00163	0.00163	CcSEcCtD
Lurasidone—Urinary tract infection—Doxorubicin—thyroid cancer	0.00161	0.00161	CcSEcCtD
Lurasidone—Urinary tract disorder—Epirubicin—thyroid cancer	0.00159	0.00159	CcSEcCtD
Lurasidone—Connective tissue disorder—Epirubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Lurasidone—Urethral disorder—Epirubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Lurasidone—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Lurasidone—Agranulocytosis—Doxorubicin—thyroid cancer	0.00155	0.00155	CcSEcCtD
Lurasidone—Bradycardia—Doxorubicin—thyroid cancer	0.00152	0.00152	CcSEcCtD
Lurasidone—Eye disorder—Epirubicin—thyroid cancer	0.0015	0.0015	CcSEcCtD
Lurasidone—Cardiac disorder—Epirubicin—thyroid cancer	0.00149	0.00149	CcSEcCtD
Lurasidone—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00147	0.00147	CcSEcCtD
Lurasidone—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Lurasidone—Angiopathy—Epirubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Lurasidone—Urethral disorder—Doxorubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Lurasidone—Arrhythmia—Epirubicin—thyroid cancer	0.00144	0.00144	CcSEcCtD
Lurasidone—Mental disorder—Epirubicin—thyroid cancer	0.00141	0.00141	CcSEcCtD
Lurasidone—Malnutrition—Epirubicin—thyroid cancer	0.0014	0.0014	CcSEcCtD
Lurasidone—Eye disorder—Doxorubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Lurasidone—Cardiac disorder—Doxorubicin—thyroid cancer	0.00138	0.00138	CcSEcCtD
Lurasidone—Flatulence—Epirubicin—thyroid cancer	0.00138	0.00138	CcSEcCtD
Lurasidone—Back pain—Epirubicin—thyroid cancer	0.00135	0.00135	CcSEcCtD
Lurasidone—Angiopathy—Doxorubicin—thyroid cancer	0.00135	0.00135	CcSEcCtD
Lurasidone—Muscle spasms—Epirubicin—thyroid cancer	0.00135	0.00135	CcSEcCtD
Lurasidone—Arrhythmia—Doxorubicin—thyroid cancer	0.00133	0.00133	CcSEcCtD
Lurasidone—Vision blurred—Epirubicin—thyroid cancer	0.00132	0.00132	CcSEcCtD
Lurasidone—Mental disorder—Doxorubicin—thyroid cancer	0.0013	0.0013	CcSEcCtD
Lurasidone—Malnutrition—Doxorubicin—thyroid cancer	0.0013	0.0013	CcSEcCtD
Lurasidone—Anaemia—Epirubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Lurasidone—Agitation—Epirubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Lurasidone—Flatulence—Doxorubicin—thyroid cancer	0.00128	0.00128	CcSEcCtD
Lurasidone—Malaise—Epirubicin—thyroid cancer	0.00126	0.00126	CcSEcCtD
Lurasidone—Vertigo—Epirubicin—thyroid cancer	0.00126	0.00126	CcSEcCtD
Lurasidone—Syncope—Epirubicin—thyroid cancer	0.00126	0.00126	CcSEcCtD
Lurasidone—Leukopenia—Epirubicin—thyroid cancer	0.00125	0.00125	CcSEcCtD
Lurasidone—Back pain—Doxorubicin—thyroid cancer	0.00125	0.00125	CcSEcCtD
Lurasidone—Muscle spasms—Doxorubicin—thyroid cancer	0.00125	0.00125	CcSEcCtD
Lurasidone—Loss of consciousness—Epirubicin—thyroid cancer	0.00123	0.00123	CcSEcCtD
Lurasidone—Vision blurred—Doxorubicin—thyroid cancer	0.00122	0.00122	CcSEcCtD
Lurasidone—Convulsion—Epirubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Lurasidone—Hypertension—Epirubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Lurasidone—Anaemia—Doxorubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Lurasidone—Myalgia—Epirubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Lurasidone—Agitation—Doxorubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Lurasidone—Anxiety—Epirubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00118	0.00118	CcSEcCtD
Lurasidone—Malaise—Doxorubicin—thyroid cancer	0.00117	0.00117	CcSEcCtD
Lurasidone—Dry mouth—Epirubicin—thyroid cancer	0.00117	0.00117	CcSEcCtD
Lurasidone—Vertigo—Doxorubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Lurasidone—Syncope—Doxorubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Lurasidone—Leukopenia—Doxorubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Lurasidone—Loss of consciousness—Doxorubicin—thyroid cancer	0.00114	0.00114	CcSEcCtD
Lurasidone—Infection—Epirubicin—thyroid cancer	0.00114	0.00114	CcSEcCtD
Lurasidone—Shock—Epirubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Lurasidone—Convulsion—Doxorubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Lurasidone—Nervous system disorder—Epirubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Lurasidone—Hypertension—Doxorubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Lurasidone—Tachycardia—Epirubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Lurasidone—Skin disorder—Epirubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Lurasidone—Hyperhidrosis—Epirubicin—thyroid cancer	0.0011	0.00111	CcSEcCtD
Lurasidone—Myalgia—Doxorubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Lurasidone—Anxiety—Doxorubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Lurasidone—Dry mouth—Doxorubicin—thyroid cancer	0.00108	0.00108	CcSEcCtD
Lurasidone—Hypotension—Epirubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Lurasidone—Infection—Doxorubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Lurasidone—Shock—Doxorubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Lurasidone—Nervous system disorder—Doxorubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Lurasidone—Insomnia—Epirubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Lurasidone—Tachycardia—Doxorubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Lurasidone—Skin disorder—Doxorubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Lurasidone—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00102	0.00102	CcSEcCtD
Lurasidone—Dyspnoea—Epirubicin—thyroid cancer	0.00102	0.00102	CcSEcCtD
Lurasidone—Somnolence—Epirubicin—thyroid cancer	0.00102	0.00102	CcSEcCtD
Lurasidone—Dyspepsia—Epirubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Lurasidone—Decreased appetite—Epirubicin—thyroid cancer	0.000994	0.000994	CcSEcCtD
Lurasidone—Hypotension—Doxorubicin—thyroid cancer	0.000988	0.000988	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000987	0.000987	CcSEcCtD
Lurasidone—Fatigue—Epirubicin—thyroid cancer	0.000985	0.000986	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000964	0.000964	CcSEcCtD
Lurasidone—Insomnia—Doxorubicin—thyroid cancer	0.000957	0.000957	CcSEcCtD
Lurasidone—Dyspnoea—Doxorubicin—thyroid cancer	0.000943	0.000943	CcSEcCtD
Lurasidone—Somnolence—Doxorubicin—thyroid cancer	0.00094	0.00094	CcSEcCtD
Lurasidone—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000935	0.000935	CcSEcCtD
Lurasidone—Dyspepsia—Doxorubicin—thyroid cancer	0.000931	0.000931	CcSEcCtD
Lurasidone—Decreased appetite—Doxorubicin—thyroid cancer	0.000919	0.000919	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000913	0.000913	CcSEcCtD
Lurasidone—Fatigue—Doxorubicin—thyroid cancer	0.000912	0.000912	CcSEcCtD
Lurasidone—Abdominal pain—Epirubicin—thyroid cancer	0.000904	0.000904	CcSEcCtD
Lurasidone—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000865	0.000865	CcSEcCtD
Lurasidone—Abdominal pain—Doxorubicin—thyroid cancer	0.000836	0.000836	CcSEcCtD
Lurasidone—Asthenia—Epirubicin—thyroid cancer	0.00082	0.00082	CcSEcCtD
Lurasidone—Pruritus—Epirubicin—thyroid cancer	0.000809	0.000809	CcSEcCtD
Lurasidone—Diarrhoea—Epirubicin—thyroid cancer	0.000782	0.000782	CcSEcCtD
Lurasidone—Asthenia—Doxorubicin—thyroid cancer	0.000759	0.000759	CcSEcCtD
Lurasidone—Dizziness—Epirubicin—thyroid cancer	0.000756	0.000756	CcSEcCtD
Lurasidone—Pruritus—Doxorubicin—thyroid cancer	0.000748	0.000748	CcSEcCtD
Lurasidone—Vomiting—Epirubicin—thyroid cancer	0.000727	0.000727	CcSEcCtD
Lurasidone—Diarrhoea—Doxorubicin—thyroid cancer	0.000724	0.000724	CcSEcCtD
Lurasidone—Rash—Epirubicin—thyroid cancer	0.000721	0.000721	CcSEcCtD
Lurasidone—Dermatitis—Epirubicin—thyroid cancer	0.00072	0.00072	CcSEcCtD
Lurasidone—Dizziness—Doxorubicin—thyroid cancer	0.000699	0.000699	CcSEcCtD
Lurasidone—Nausea—Epirubicin—thyroid cancer	0.000679	0.000679	CcSEcCtD
Lurasidone—Vomiting—Doxorubicin—thyroid cancer	0.000672	0.000672	CcSEcCtD
Lurasidone—Rash—Doxorubicin—thyroid cancer	0.000667	0.000667	CcSEcCtD
Lurasidone—Dermatitis—Doxorubicin—thyroid cancer	0.000666	0.000666	CcSEcCtD
Lurasidone—Nausea—Doxorubicin—thyroid cancer	0.000628	0.000628	CcSEcCtD
Lurasidone—ADRA2A—GPCR ligand binding—CALCA—thyroid cancer	1.7e-07	0.00265	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CALCB—thyroid cancer	1.66e-07	0.00259	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—CALCA—thyroid cancer	1.65e-07	0.00257	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CALCB—thyroid cancer	1.63e-07	0.00255	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—TSHR—thyroid cancer	1.63e-07	0.00255	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—IFNA2—thyroid cancer	1.63e-07	0.00254	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TCF7L1—thyroid cancer	1.61e-07	0.00252	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—TSHR—thyroid cancer	1.58e-07	0.00246	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TRIM33—thyroid cancer	1.57e-07	0.00246	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—SST—thyroid cancer	1.55e-07	0.00243	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TRIM33—thyroid cancer	1.55e-07	0.00242	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—CALCA—thyroid cancer	1.49e-07	0.00234	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CALCB—thyroid cancer	1.48e-07	0.00232	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—TSHR—thyroid cancer	1.48e-07	0.00231	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—PRKAR1A—thyroid cancer	1.46e-07	0.00227	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—TSHR—thyroid cancer	1.43e-07	0.00224	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—TSHR—thyroid cancer	1.43e-07	0.00224	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—HPGD—thyroid cancer	1.43e-07	0.00224	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PRKAR1A—thyroid cancer	1.41e-07	0.0022	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—TSHR—thyroid cancer	1.41e-07	0.0022	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TRIM33—thyroid cancer	1.41e-07	0.0022	CbGpPWpGaD
Lurasidone—HTR7—Circadian rythm related genes—TP53—thyroid cancer	1.35e-07	0.00212	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—CDK1—thyroid cancer	1.35e-07	0.00211	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—IFNA2—thyroid cancer	1.32e-07	0.00206	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—TSHR—thyroid cancer	1.3e-07	0.00203	CbGpPWpGaD
Lurasidone—DRD2—Circadian rythm related genes—PTEN—thyroid cancer	1.29e-07	0.00202	CbGpPWpGaD
Lurasidone—CYP3A4—Biological oxidations—RXRA—thyroid cancer	1.29e-07	0.00201	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—TSHR—thyroid cancer	1.28e-07	0.002	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—TSHR—thyroid cancer	1.28e-07	0.002	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PRKAR1A—thyroid cancer	1.28e-07	0.002	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—SST—thyroid cancer	1.27e-07	0.00198	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—PTCH1—thyroid cancer	1.26e-07	0.00197	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PRKAR1A—thyroid cancer	1.26e-07	0.00197	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—SST—thyroid cancer	1.23e-07	0.00192	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—CALCA—thyroid cancer	1.22e-07	0.00191	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PTCH1—thyroid cancer	1.22e-07	0.0019	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TCF7L1—thyroid cancer	1.19e-07	0.00187	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—CALCA—thyroid cancer	1.18e-07	0.00184	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TSHR—thyroid cancer	1.18e-07	0.00184	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—TSHR—thyroid cancer	1.16e-07	0.00182	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PRKAR1A—thyroid cancer	1.16e-07	0.00181	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TCF7L1—thyroid cancer	1.16e-07	0.00181	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—SST—thyroid cancer	1.15e-07	0.0018	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PRKAR1A—thyroid cancer	1.14e-07	0.00179	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—SST—thyroid cancer	1.11e-07	0.00174	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—SST—thyroid cancer	1.11e-07	0.00174	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MEN1—thyroid cancer	1.11e-07	0.00173	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CALCA—thyroid cancer	1.11e-07	0.00173	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PTCH1—thyroid cancer	1.1e-07	0.00173	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—SST—thyroid cancer	1.09e-07	0.00171	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PTCH1—thyroid cancer	1.09e-07	0.0017	CbGpPWpGaD
Lurasidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	1.07e-07	0.00168	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CALCA—thyroid cancer	1.07e-07	0.00167	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—CALCA—thyroid cancer	1.07e-07	0.00167	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—CALCA—thyroid cancer	1.05e-07	0.00165	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TCF7L1—thyroid cancer	1.05e-07	0.00164	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TCF7L1—thyroid cancer	1.03e-07	0.00161	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—TPR—thyroid cancer	1.01e-07	0.00158	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—SST—thyroid cancer	1.01e-07	0.00158	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PTCH1—thyroid cancer	1e-07	0.00157	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CDK1—thyroid cancer	1e-07	0.00157	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—SST—thyroid cancer	9.96e-08	0.00156	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PRKAR1A—thyroid cancer	9.95e-08	0.00156	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—SST—thyroid cancer	9.94e-08	0.00155	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PTCH1—thyroid cancer	9.89e-08	0.00155	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CALCA—thyroid cancer	9.72e-08	0.00152	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CDK1—thyroid cancer	9.7e-08	0.00152	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CALCA—thyroid cancer	9.58e-08	0.0015	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CALCA—thyroid cancer	9.57e-08	0.0015	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—MINPP1—thyroid cancer	9.45e-08	0.00148	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TCF7L1—thyroid cancer	9.38e-08	0.00147	CbGpPWpGaD
Lurasidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	9.24e-08	0.00144	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—SST—thyroid cancer	9.17e-08	0.00143	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—SST—thyroid cancer	9.04e-08	0.00141	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CALCA—thyroid cancer	8.83e-08	0.00138	CbGpPWpGaD
Lurasidone—DRD2—Circadian rythm related genes—TP53—thyroid cancer	8.81e-08	0.00138	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CDK1—thyroid cancer	8.8e-08	0.00138	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TSHR—thyroid cancer	8.74e-08	0.00137	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CALCA—thyroid cancer	8.7e-08	0.00136	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CDK1—thyroid cancer	8.66e-08	0.00135	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PRKAR1A—thyroid cancer	8.6e-08	0.00134	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TSHR—thyroid cancer	8.46e-08	0.00132	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PRKAR1A—thyroid cancer	8.32e-08	0.0013	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MEN1—thyroid cancer	8.22e-08	0.00128	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—TPR—thyroid cancer	8.21e-08	0.00128	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PRKAR1A—thyroid cancer	8.08e-08	0.00126	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NDUFA13—thyroid cancer	8.04e-08	0.00126	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CDK1—thyroid cancer	7.99e-08	0.00125	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MEN1—thyroid cancer	7.95e-08	0.00124	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CDK1—thyroid cancer	7.88e-08	0.00123	CbGpPWpGaD
Lurasidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	7.85e-08	0.00123	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TSHR—thyroid cancer	7.67e-08	0.0012	CbGpPWpGaD
Lurasidone—ADRA2C—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	7.6e-08	0.00119	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—SLC5A5—thyroid cancer	7.57e-08	0.00118	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CHST14—thyroid cancer	7.56e-08	0.00118	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TSHR—thyroid cancer	7.55e-08	0.00118	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PRKAR1A—thyroid cancer	7.55e-08	0.00118	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PTCH1—thyroid cancer	7.43e-08	0.00116	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PRKAR1A—thyroid cancer	7.43e-08	0.00116	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MEN1—thyroid cancer	7.21e-08	0.00113	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PTCH1—thyroid cancer	7.19e-08	0.00112	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MEN1—thyroid cancer	7.1e-08	0.00111	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TSHR—thyroid cancer	6.87e-08	0.00107	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SST—thyroid cancer	6.8e-08	0.00106	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PRKAR1A—thyroid cancer	6.76e-08	0.00106	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SST—thyroid cancer	6.58e-08	0.00103	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CALCA—thyroid cancer	6.54e-08	0.00102	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PTCH1—thyroid cancer	6.52e-08	0.00102	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MEN1—thyroid cancer	6.46e-08	0.00101	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PTCH1—thyroid cancer	6.42e-08	0.001	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NRG1—thyroid cancer	6.41e-08	0.001	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—RXRA—thyroid cancer	6.36e-08	0.000994	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CALCA—thyroid cancer	6.33e-08	0.000989	CbGpPWpGaD
Lurasidone—ADRA2A—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	6.17e-08	0.000965	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—SLC5A5—thyroid cancer	6.15e-08	0.000961	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HPGD—thyroid cancer	6.09e-08	0.000952	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—NRAS—thyroid cancer	6.06e-08	0.000948	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SST—thyroid cancer	5.97e-08	0.000933	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDK1—thyroid cancer	5.92e-08	0.000926	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SST—thyroid cancer	5.87e-08	0.000918	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PTCH1—thyroid cancer	5.84e-08	0.000913	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TERT—thyroid cancer	5.76e-08	0.0009	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CALCA—thyroid cancer	5.74e-08	0.000898	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDK1—thyroid cancer	5.73e-08	0.000896	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CALCA—thyroid cancer	5.65e-08	0.000883	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—HIF1A—thyroid cancer	5.51e-08	0.000861	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SST—thyroid cancer	5.34e-08	0.000835	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—KRAS—thyroid cancer	5.22e-08	0.000816	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDK1—thyroid cancer	5.2e-08	0.000813	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—RXRA—thyroid cancer	5.17e-08	0.000808	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CALCA—thyroid cancer	5.14e-08	0.000804	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDK1—thyroid cancer	5.12e-08	0.0008	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—NRAS—thyroid cancer	4.92e-08	0.00077	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—NRAS—thyroid cancer	4.85e-08	0.000758	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NRG1—thyroid cancer	4.75e-08	0.000743	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDK1—thyroid cancer	4.65e-08	0.000727	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—TP53—thyroid cancer	4.64e-08	0.000725	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NRG1—thyroid cancer	4.6e-08	0.000719	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—BRAF—thyroid cancer	4.56e-08	0.000713	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—HRAS—thyroid cancer	4.43e-08	0.000693	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TERT—thyroid cancer	4.27e-08	0.000667	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—KRAS—thyroid cancer	4.24e-08	0.000662	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—KRAS—thyroid cancer	4.18e-08	0.000653	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NRG1—thyroid cancer	4.17e-08	0.000652	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TERT—thyroid cancer	4.13e-08	0.000645	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NRG1—thyroid cancer	4.11e-08	0.000642	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—HIF1A—thyroid cancer	4.08e-08	0.000638	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PPARG—thyroid cancer	4.02e-08	0.000628	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—HIF1A—thyroid cancer	3.95e-08	0.000617	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—AKT1—thyroid cancer	3.92e-08	0.000612	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—TP53—thyroid cancer	3.77e-08	0.000589	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TERT—thyroid cancer	3.75e-08	0.000586	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NRG1—thyroid cancer	3.74e-08	0.000584	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TERT—thyroid cancer	3.69e-08	0.000576	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—HRAS—thyroid cancer	3.6e-08	0.000563	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—NRAS—thyroid cancer	3.6e-08	0.000562	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HIF1A—thyroid cancer	3.58e-08	0.00056	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—HRAS—thyroid cancer	3.55e-08	0.000555	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HIF1A—thyroid cancer	3.53e-08	0.000551	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—TPR—thyroid cancer	3.5e-08	0.000547	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—NRAS—thyroid cancer	3.48e-08	0.000544	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—AKT1—thyroid cancer	3.45e-08	0.000539	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	3.44e-08	0.000538	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—BRAF—thyroid cancer	3.38e-08	0.000528	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TERT—thyroid cancer	3.35e-08	0.000524	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CCND1—thyroid cancer	3.33e-08	0.00052	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—BRAF—thyroid cancer	3.27e-08	0.000511	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PPARG—thyroid cancer	3.26e-08	0.00051	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PTEN—thyroid cancer	3.21e-08	0.000502	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HIF1A—thyroid cancer	3.21e-08	0.000501	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—AKT1—thyroid cancer	3.18e-08	0.000497	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTGS2—thyroid cancer	3.16e-08	0.000494	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—NRAS—thyroid cancer	3.16e-08	0.000493	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—AKT1—thyroid cancer	3.13e-08	0.00049	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—NRAS—thyroid cancer	3.11e-08	0.000486	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—KRAS—thyroid cancer	3.09e-08	0.000484	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—KRAS—thyroid cancer	2.99e-08	0.000468	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—BRAF—thyroid cancer	2.97e-08	0.000464	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—BRAF—thyroid cancer	2.92e-08	0.000456	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NRAS—thyroid cancer	2.87e-08	0.000448	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—NRAS—thyroid cancer	2.83e-08	0.000442	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTEN—thyroid cancer	2.75e-08	0.000431	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—KRAS—thyroid cancer	2.72e-08	0.000425	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	2.67e-08	0.000418	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—BRAF—thyroid cancer	2.66e-08	0.000415	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—HRAS—thyroid cancer	2.63e-08	0.000411	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.62e-08	0.000409	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTGS2—thyroid cancer	2.57e-08	0.000401	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—AKT1—thyroid cancer	2.56e-08	0.0004	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—HRAS—thyroid cancer	2.55e-08	0.000398	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—AKT1—thyroid cancer	2.47e-08	0.000387	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—KRAS—thyroid cancer	2.47e-08	0.000386	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCND1—thyroid cancer	2.47e-08	0.000386	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—KRAS—thyroid cancer	2.43e-08	0.00038	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCND1—thyroid cancer	2.39e-08	0.000373	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PTEN—thyroid cancer	2.38e-08	0.000372	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—AKT1—thyroid cancer	2.32e-08	0.000363	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—HRAS—thyroid cancer	2.31e-08	0.000361	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PTEN—thyroid cancer	2.3e-08	0.00036	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	2.27e-08	0.000355	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—AKT1—thyroid cancer	2.25e-08	0.000351	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—AKT1—thyroid cancer	2.25e-08	0.000351	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTEN—thyroid cancer	2.24e-08	0.00035	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	2.21e-08	0.000345	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—RXRA—thyroid cancer	2.2e-08	0.000344	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TP53—thyroid cancer	2.19e-08	0.000343	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCND1—thyroid cancer	2.17e-08	0.000339	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCND1—thyroid cancer	2.13e-08	0.000333	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NRAS—thyroid cancer	2.12e-08	0.000332	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—HRAS—thyroid cancer	2.1e-08	0.000328	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PTEN—thyroid cancer	2.09e-08	0.000327	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—HRAS—thyroid cancer	2.07e-08	0.000323	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PTEN—thyroid cancer	2.06e-08	0.000321	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NRAS—thyroid cancer	2.06e-08	0.000321	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—AKT1—thyroid cancer	2.04e-08	0.000319	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—AKT1—thyroid cancer	2.01e-08	0.000314	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	2.01e-08	0.000314	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCND1—thyroid cancer	1.94e-08	0.000303	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PTEN—thyroid cancer	1.87e-08	0.000292	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NRAS—thyroid cancer	1.86e-08	0.000291	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—AKT1—thyroid cancer	1.85e-08	0.000289	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NRAS—thyroid cancer	1.83e-08	0.000287	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—KRAS—thyroid cancer	1.83e-08	0.000286	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—AKT1—thyroid cancer	1.83e-08	0.000285	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—KRAS—thyroid cancer	1.77e-08	0.000277	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NRAS—thyroid cancer	1.67e-08	0.000261	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TP53—thyroid cancer	1.62e-08	0.000254	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KRAS—thyroid cancer	1.6e-08	0.000251	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—AKT1—thyroid cancer	1.59e-08	0.000248	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KRAS—thyroid cancer	1.58e-08	0.000247	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TP53—thyroid cancer	1.57e-08	0.000246	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—HRAS—thyroid cancer	1.55e-08	0.000243	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—HRAS—thyroid cancer	1.5e-08	0.000235	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KRAS—thyroid cancer	1.44e-08	0.000225	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TP53—thyroid cancer	1.43e-08	0.000223	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TP53—thyroid cancer	1.4e-08	0.000219	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PPARG—thyroid cancer	1.39e-08	0.000217	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AKT1—thyroid cancer	1.37e-08	0.000214	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HRAS—thyroid cancer	1.36e-08	0.000213	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HRAS—thyroid cancer	1.34e-08	0.00021	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AKT1—thyroid cancer	1.33e-08	0.000208	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AKT1—thyroid cancer	1.29e-08	0.000202	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TP53—thyroid cancer	1.28e-08	0.0002	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HRAS—thyroid cancer	1.22e-08	0.000191	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AKT1—thyroid cancer	1.2e-08	0.000188	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AKT1—thyroid cancer	1.19e-08	0.000185	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.09e-08	0.000171	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKT1—thyroid cancer	1.08e-08	0.000169	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTEN—thyroid cancer	9.53e-09	0.000149	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKT1—thyroid cancer	5.49e-09	8.59e-05	CbGpPWpGaD
